Mammalian Cell Fermentation Technology Market Analysis

Mammalian Cell Fermentation Technology Market Analysis

To get key market trends

  Download Free Sample

By type, the mammalian cell fermentation technology market is segmented into Chinese hamster ovary (CHO) cell fermentation, human embryonic kidney (HEK) cell fermentation, baby hamster kidney (BHK) cell fermentation, murine myeloma cell fermentation, and other types. The Chinese hamster Ovary (CHO) cell fermentation segment held largest market share of 65.2% in 2022. CHO cells have garnered immense attention due to their capacity to efficiently produce complex therapeutic proteins. The surge in demand can be attributed to several factors, including advancements in genetic engineering techniques for enhancing cell line development, optimization of culture media and conditions, and a robust regulatory environment. The versatility of CHO cells in producing monoclonal antibodies, vaccines, and other biologics has positioned them as the preferred choice for many pharmaceutical and biotechnology companies, thereby aiding in high segment growth.
 

By application, the mammalian cell fermentation technology market is segmented into monoclonal antibodies, recombinant proteins, vaccines, hormones, enzymes, and other applications. The monoclonal antibodies segment held highest business share of 41.9% in 2022. High adoption can be attributed to the pivotal role that antibodies play in therapeutic and diagnostic applications, leading to increased demand for efficient production methods. Also, segment's rapid growth is fuelled by advancements in bioprocessing techniques, cell line development, and bioreactor technologies, resulting in enhanced yields, improved product quality, and streamlined production processes. Moreover, the rising prevalence of chronic diseases and the need for precise targeted therapies have further amplified the demand for mammalian antibodies.
 

Based on end-use, the mammalian cell fermentation technology market is segmented into CMOs & CDMOs, biopharmaceutical companies, and academic & research institutes. The CMOs & CDMOs segment dominated the market in 2022 with a revenue of USD 19.8 billion. High demand for CMOs & CDMOs can be attributed to advanced manufacturing capabilities that CMOs and CDMOs specialize in. These organizations offer a streamlined and cost-effective approach for companies aiming to outsource their production processes, enabling them to focus on research and development.
 

Moreover, regulatory requirements and quality standards have become more stringent, making it vital for pharmaceutical companies to collaborate with established CMOs and CDMOs that possess the expertise to meet these standards. Further, as the biopharmaceutical sector continues to expand, the CMOs and CDMOs specializing in mammalian cell fermentation are poised to play a pivotal role in shaping the industry's landscape, driving innovation, and ensuring the efficient delivery of cutting-edge therapies to patients across the globe.
 

North America dominated the mammalian cell fermentation technology market in 2022, with a revenue of USD 18.2 billion and is anticipated to grow at a CAGR of 7.9% between 2023 – 2032. This growth can be attributed to the thriving biopharmaceutical industry in the region. The region's focus on innovation, coupled with a strong foundation in scientific expertise and infrastructure, has propelled it to the forefront of market growth. Moreover, favorable regulatory frameworks, increased investment in biotechnology R&D, growing demand for biologics and personalized medicine have further propelled the North American market expansion.